EUVIMEDEUVIMED entdecken
Crossref

Sorafenib-induced Pemphigus Vulgaris

Ajay Deshpande

Indian Journal of Drugs in Dermatology · 2016

DOI: 10.4103/2455-3972.196172 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Drugs in Dermatology, 2016. Verfasst von Ajay Deshpande. Die Arbeit nennt 6 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sorafenib is a tyrosine kinase inhibitor approved for the treatment of primary kidney cancer, advanced primary hepatocellular carcinoma and radioactive iodine-resistant advanced thyroid carcinoma. Sorafenib is known to cause milder cutaneous side effects such as maculopapular rash and serious cutaneous drug reactions such as desquamation of the skin, hand-foot syndrome Stevens-Johnsons syndrome and toxic epidermal necrolysis. We report a histopathologicaly proved case of pemphigus vulgaris caused by sorafenib.

Zitieren

APA

Deshpande, A. (2016). Sorafenib-induced Pemphigus Vulgaris. Indian Journal of Drugs in Dermatology. https://doi.org/10.4103/2455-3972.196172

Vancouver

Deshpande A. Sorafenib-induced Pemphigus Vulgaris. Indian Journal of Drugs in Dermatology. 2016. doi:10.4103/2455-3972.196172

BibTeX
@article{Deshpande2016,
  author = {Deshpande, Ajay},
  title = {Sorafenib-induced Pemphigus Vulgaris},
  journal = {Indian Journal of Drugs in Dermatology},
  year = {2016},
  doi = {10.4103/2455-3972.196172}
}
Kostenlos starten →